Skip to content
No picture yet

Mar-Ranitidine 150 mg – DIN 02443708

Mar-Ranitidine is Ranitidine Hydrochloride 150 mg (tablet), sold in Canada. It is used for acid reflux (GERD), ulcers and stomach ulcers. It is supplied by Marcan Pharmaceuticals Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Ranitidine Hydrochloride 150 mg

Brand
Mar-Ranitidine
Strength
150 mg
Used for
Acid reflux (GERD), ulcers and stomach ulcers
Form
Tablet
Manufacturer
Marcan Pharmaceuticals Inc
Drug class
Acid reducer (H2 blocker)
Sold in
Canada
DIN
02443708

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Ranitidine pills and guides

What is Ranitidine used for?

Ranitidine is used for acid reflux (GERD), ulcers, stomach ulcers and Zollinger-Ellison syndrome.

Medicine type
Acid reducer (H2 blocker)
Official uses from the US prescribing label

Ranitidine Tablets are indicated in:

  1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks.
  2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo – controlled comparative studies have been carried out for periods longer than 1 year.
  3. The treatment of pathological hypersecretory conditions. (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).
  4. Short-term treatment of active, benign gastric ulcers. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks.
  5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year.
  6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets USP, 150 mg twice daily.
  7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets USP, 150 mg 4 times daily.
  8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks.

​​​​​​​Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

From the FDA-approved label on DailyMed (published Sep 25, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02443708.
  • It names Mar-Ranitidine, Ranitidine Hydrochloride 150 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Mar-Ranitidine by Marcan Pharmaceuticals Inc.

In Canada: prescription only.

Ingredients

Active: Ranitidine (Ranitidine Hydrochloride)

Other Ranitidine pills